EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma

Jennifer A Lenz iD, Laurel Upton iD, Jonathan Ma iD, Mia M Talone iD, Brandon Peng iD, Lang Jiang iD, Audrey Ghanian iD, Dillon Didehvar iD, Ester Yang iD, Joseph A Fraietta iD, Matthew J Atherton iD

Journal of Veterinary Internal Medicine · 02.11.2026 · 40 (6)

DOI: 10.1093/jvimsj/aalag283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 02.11.2026. Verfasst von Jennifer A Lenz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Dog Diseases, Lymphoma, Antineoplastic Agents, Alkylating. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH/National Cancer Institute (NCI) Career Development, NCATS NIH HHS, Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine and the School of Veterinary Medicine at the University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for many human patients with B-cell lymphoma and provides a rational template for analogous canine patients. To date, the expansion, persistence, and activity of CAR T cells in dogs have been limited. Lymphodepletion supports CAR T-cell engraftment and antitumor activity. In human medical oncology, bendamustine has emerged as a well-tolerated lymphodepleting agent. However, prospective use of bendamustine for dogs with lymphoma has not been characterized. Hypothesis/Objectives To determine the lymphodepleting activity and tolerability of bendamustine in dogs with relapsed lymphoma. Secondary objectives included monitoring serum cytokines and short-term changes in peripheral tumor burden. Animals Eleven client-owned dogs with relapsed lymphoma.

Methods

Luminescent assays were used to assess the direct cytotoxic activity of bendamustine against canine lymphoid cell lines. A prospective rapid dose-escalation pilot trial was undertaken in 11 dogs with relapsed lymphoma to evaluate tolerability while tracking peripheral lymphocyte counts, serum cytokine concentrations, and lymph node measurements.

Results

Bendamustine induced concentration-dependent cytotoxicity in all cell lines tested. Two-dose bendamustine regimens up to 90 mg/m2 were generally well tolerated, with no dose-limiting toxicities observed, and resulted in peripheral lymphodepletion (pretreatment median, 880 cells/μL; posttreatment median, 310 cells/μL), an exploratory decrease in circulating interleukin-6 (pretreatment median, 5.32 pg/mL; posttreatment median, 1.33 pg/mL), and a short-term decrease in peripheral nodal burden in 8 of 11 dogs. Conclusions and clinical importance Bendamustine was generally well tolerated and induced lymphodepletion in our cohort. These findings support further evaluation of bendamustine as a preconditioning agent before autologous canine CAR T-cell infusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideDog DiseasesLymphomaAntineoplastic Agents, AlkylatingLymphocyte DepletionAnimalsDogsFemaleMaleNeoplasm Recurrence, LocalCell Line, TumorProspective StudiesPilot ProjectsCytokines

Stichwörter der Autor:innen

bendamustinecanine lymphomalymphodepletionpreconditioning

Substanzen

Bendamustine HydrochlorideAntineoplastic Agents, AlkylatingCytokines

Autor:innen und Institutionen

  • Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

ORCID-Profile: Jennifer A Lenz, Laurel Upton, Jonathan Ma, Mia M Talone, Brandon Peng, Lang Jiang, Audrey Ghanian, Dillon Didehvar, Ester Yang, Joseph A Fraietta, Matthew J Atherton

Förderung

  • NIH/National Cancer Institute (NCI) Career Development
  • NCATS NIH HHS
  • Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine and the School of Veterinary Medicine at the University of Pennsylvania
  • National Center for Advancing Translational Sciences of the National Institutes of Health (NIH)
  • NCI NIH HHS

Zitieren

APA

Lenz, J. A., Upton, L., Ma, J., Talone, M. M., Peng, B., Jiang, L., Ghanian, A., Didehvar, D., Yang, E., Fraietta, J. A., & Atherton, M. J. (2026). Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine, 40(6). https://doi.org/10.1093/jvimsj/aalag283

Vancouver

Lenz JA, Upton L, Ma J, Talone MM, Peng B, Jiang L, et al. Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine. 2026;40(6). doi:10.1093/jvimsj/aalag283

BibTeX
@article{Lenz2026,
  author = {Lenz, Jennifer A and Upton, Laurel and Ma, Jonathan and Talone, Mia M and Peng, Brandon and Jiang, Lang and Ghanian, Audrey and Didehvar, Dillon and Yang, Ester and Fraietta, Joseph A and Atherton, Matthew J},
  title = {Bendamustine induces peripheral lymphodepletion in dogs with relapsed lymphoma},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {6},
  doi = {10.1093/jvimsj/aalag283}
}
Kostenlos starten →